Mediators of Inflammation / 2020 / Article / Tab 3

Research Article

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Table 3

Current treatment and ocular data regarding scleritis grading and number of relapses in our cohort of patients.

PatientOngoing treatment and dosageIndicationTreatment duration (months)Scleritis grading before therapy
Scleritis grading at last follow-up
Scleritis grading before therapy
Scleritis grading at last follow-up
No. of relapses 12 months preceding therapyNo. of relapses after 12 months of therapyNo. of relapses at last follow-upcDMARDsGCs§AE

2RTX 2 grScleritis1403NC0#
4RTX 2 gr/6 monthsScleritis12343
5RTX 2 gr/6 monthsSystemic302010AZA
6TCZ 162 mg/weekScleritis300203NC0
7TCZ 162 mg/weekScleritis2820415
8ANA 100 mg/dayScleritis1433NC02.5
9ANA 100 mg/dayScleritis340003NC0MTX12.5
10ANA 100 mg/dayScleritis441010
11ABA 125 mg/weekSystemic24443343
12ABA 125 mg/weekSystemic561010MTX
13ABA 125 mg/weekSystemic152010MTX
14TFC 5 mg twice dailySystemic600201NC5

ABA: abatacept; ANA: anakinra; AE: adverse event; AZA: azathioprine; cDMARDs: conventional disease-modifying antirheumatic drugs; GCs: glucocorticoids; LE: left eye; LFN: leflunomide; MFA: mycophenolic acid; MTX: methotrexate; No.: number; NC: not calculable; RE: right eye; RTX: rituximab; TCZ: tocilizumab; TFC: tofacitinib. 2 loading dose infusions of 1000 mg separated by 2 weeks and 500 mg every 6 months thereafter. #Pneumonia and septic shock. §Daily intake of glucocorticoids (prednisone or equivalent expressed in mg).

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.